Business Case

Developed drivers and potential barriers of Hematologist GTx adoption to understand the impacts on patient adoption and inform strategic commercialization planning for a mid-sized biotech

The Italian subsidiary of a mid-sized, independent gene therapy company, sought to understand the intricacies of the hematologist GTx adoption and its subsequent impact on patient interest and use. LSC conducted a deep-dive analysis in key regions, quantifying epidemiological patient funnels, modeling patient flows, and examining possible cash-flow challenges to identify a thorough list of drivers and potential barriers. As a result, LSC was able to offer actionable recommendations to both understand and address the multifaceted challenges and opportunities, ensuring the company was well-prepared for strategic commercialization planning.